Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort

Journal of Psychosomatic Research

Volumn 79, Issue 6, 2015, Pages 640-645

  Whale, Richard ^a,b   Fialho, Renata ^b,c   Rolt, Michael ^b,c   Eccles, Jessica ^a,b   Pereira, Marco ^d   Keller, Majella ^e   File, Alexandra ^e   Haq, Inam ^e   Tibble, Jeremy ^e  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b SUSSEX PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e Worthing Hospital   (United Kingdom)

Author keywords

Depressive disorder; Hepatitis C; Inflammation; Interferon alpha; Prospective studies

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CHRONIC HEPATITIS C; DEPERSONALIZATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPOCHONDRIASIS; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; PARANOIA; PROSPECTIVE STUDY; PSYCHOMOTOR RETARDATION; SEX DIFFERENCE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUICIDE; UROGENITAL TRACT DISEASE; CHEMICALLY INDUCED; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR PERFORMANCE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; RIBAVIRIN;

EID: 84932110454     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2015.06.003     Document Type: Article

References (42)

1. Lavanchy D Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2001, 17:107-115.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha 2-b plus ribavirin compared with interferon alpha 2-a plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
3. Krishnadas R, Cavanagh J Depression: an inflammatory illness?. J Neurol Neurosurg Psychiatry 2012, 83:495-502.
4. Udina M, Castellvi P, Moreno-España J, Navinés R, Valdés M, Forns X, et al. Interferon induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012, 73:1128-1138.
5. Zhu CB, Blakely RD, Hewlett WA The proinflammatory cytokines interleukin-1b and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.
6. Miller AH, Maletic V, Raison CL Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
7. Myint AM, Bondy B, Baghai TC, Eser D, Nothdurfter C, Schüle C, et al. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-γ gene. Brain Behav Immun 2013, 31:128-133.
8. Taylor MJ, Godlewska B, Near J, Christmas D, Potokar J, Collier J, et al. Effect of interferon-α on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study. Psychol Med 2014, 44:789-795.
9. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 2010, 15:535-547.
10. Ping F, Shang J, Zhou J, Zhang H, Zhang L 5HT (1-A) receptor and apoptosis contribute to interferon alpha induced 'depression-like' behaviour in mice. Neurosci Lett 2012, 514:173-178.
11. Dieperink E, Willenbring M, Ho SB Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157:867-886.
12. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000, 49:311-317.
13. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, et al. A prospective study of the incidence and open-label treatment of interferon induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7:942-947.
14. Horikawa N, Yamazaki T, Izumi N, Uchihara M Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003, 25:34-38.
15. Su K-P, Huang S-Y, Peng C-Y, Lai H-C, Huang C-L, Chen Y-C, et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulation polyunsaturated fatty acids levels. Biol Psychiatry 2010, 67:550-557.
16. Lotrich FE, Ferrel RE, Rabinovitz M, Pollock BJ Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009, 65:344-348.
17. Eccles J, Lallement C, Mustaq F, Greenwood M, Keller M, Golding B, et al. Pre treatment waking cortisol response and vulnerability to interferon alpha induced depression. Eur Neuropsychopharmacol 2012, 22:892-896.
18. Leutscher PD, Lagging M, Buhl MR, Pederson C, Norkrans G, Langeland N, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010, 52:430-435.
19. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
20. McNutt MD, Liu S, Manatunga A, Royster EB, Raison CL, Woolwine BJ, et al. Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology 2012, 37:1444-1454.
21. First MB, Spitzer RL, Gibbon M, Williams JBW Structured clinical interview for DSM-IV Axis I disorders, clinician version (SCID-CV) 1996, American Psychiatric Press Inc., Washington DC.
22. Hamilton M A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
23. Castellvi P, Navinés R, Gutierrez F, Jiménez D, Márquez C, Subirà S, et al. Pegylated interferon and ribavirin induced depression in chronic hepatitis C: a role of personality. J Clin Psychiatry 2009, 70:817-828.
24. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999, 156:1120.
25. Raison CL, Demetrashvili M, Capuron L, Miller AH Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123.
26. Mahajan S, Avasthi A, Grover S, Chawla YK Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection. J Psychosom Res 2014, 77:109-115.
27. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 2008, 63:1022-1029.
28. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999, 100:34-41.
29. Hultgren C, Desombere I, Leroux-Roels G, Quiroga JA, Carreno V, Nilsson B, et al. Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol 2004, 40:971-978.
30. Maes M Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:664-675.
31. Blume J, Douglas SD, Evans DL Immune suppression and immune activation in depression. Brain Behav Immun 2011, 25:221-229.
32. Cunha EC, Behrensdorf MF, Bavaresco V, Zambrano DN, Bellini J, Kaster MP, et al. Genotype 1 of hepatitis C virus increases the risk of major depression: a 12-week prospective study. Gen Hosp Psychiatry 2015, 10.1016/j.genhosppsych.2015.03.016.
33. Franzen PL, Buyss DJ, Rabinovitz M, Pollock BG, Lotrich FE Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res 2010, 177:240-245.
34. Prather AA, Rabinovitz M, Pollock BG, Lotrich FE Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun 2009, 23:1109-1116.
35. Baraldi S, Hepgul N, Mondelli V, Pariante CM Symptomatic treatment of interferon-α-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol 2012, 32:531-543.
36. Sarkar S, Schaefer M Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis. Psychosomatics 2014, 55:221-234.
37. Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005, 66:1050-1057.
38. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008, 118:347-356.
39. Peles E, Schreiber S, Naumovsky Y, Adelson M Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord 2007, 99:213-220.
40. Oddy WH, Hickling S, Smith MA, O'Sullivan TA, Robinson M, de Klerk NH, et al. Dietary intake of omega-3 fatty acids and risk of depressive symptoms in adolescents. Depress Anxiety 2011, 28:582-588.
41. Chayama K, Mitsui F, Hayes CN Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2015, 9:21-30.
42. Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz J-M, Dayer P Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG screening outcome in psychiatry study. Am J Psychiatry 2013, 170:1468-1476.